138 related articles for article (PubMed ID: 37095413)
1. Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers.
Abdalla TSA; Klinkhammer-Schalke M; Zeissig SR; Tol KK; Honselmann KC; Braun R; Bolm L; Lapshyn H; Litkevych S; Zemskov S; Begum N; Kulemann B; Hummel R; Wellner UF; Keck T; Deichmann S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8535-8543. PubMed ID: 37095413
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies.
Watzka FM; Meyer F; Staubitz JI; Fottner C; Schad A; Lang H; Musholt TJ
World J Surg; 2020 Feb; 44(2):594-603. PubMed ID: 31605171
[TBL] [Abstract][Full Text] [Related]
3. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
[TBL] [Abstract][Full Text] [Related]
4. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
5. Reconsideration of operative indications in pancreatic neuroendocrine neoplasms.
Abe K; Kitago M; Iwasaki E; Yagi H; Abe Y; Hasegawa Y; Hori S; Tanaka M; Nakano Y; Kitagawa Y
World J Surg Oncol; 2022 Nov; 20(1):366. PubMed ID: 36397094
[TBL] [Abstract][Full Text] [Related]
6. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
7. Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.
Mintziras I; Keck T; Werner J; Fichtner-Feigl S; Wittel U; Senninger N; Vowinkel T; Köninger J; Anthuber M; Geißler B; Bartsch DK;
Surg Today; 2019 Dec; 49(12):1013-1021. PubMed ID: 31240463
[TBL] [Abstract][Full Text] [Related]
8. Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.
Lindner K; Binte D; Hoeppner J; Wellner UF; Schulte DM; Schmid SM; Luley K; Buchmann I; Tharun L; Keck T; Gebauer J; Kulemann B
Curr Oncol; 2021 Aug; 28(4):3071-3080. PubMed ID: 34436034
[TBL] [Abstract][Full Text] [Related]
9. Comparison of morphological features in lymph node metastasis between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinomas.
Takahashi D; Kojima M; Morisue R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Ikeda M; Ochiai A
Pancreatology; 2020 Jul; 20(5):936-943. PubMed ID: 32553561
[TBL] [Abstract][Full Text] [Related]
10. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
12. Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm.
Horiguchi S; Kato H; Shiraha H; Tsutsumi K; Yamamoto N; Matsumoto K; Tomoda T; Uchida D; Akimoto Y; Mizukawa S; Tanaka T; Ichimura K; Takaki A; Yagi T; Okada H
J Gastroenterol Hepatol; 2017 Apr; 32(4):925-931. PubMed ID: 27637470
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
14. [The diagnosis and treatment of pancreatic neuroendocrine neoplasms].
Zhang RC; Mou YP; Xu XW; Yan JF; Chen QL
Zhonghua Wai Ke Za Zhi; 2013 Sep; 51(9):784-7. PubMed ID: 24330955
[TBL] [Abstract][Full Text] [Related]
15. Neuropilin-1 (NRP-1) upregulated by IL-6/STAT3 signaling contributes to invasion in pancreatic neuroendocrine neoplasms.
Yang Y; Yang L; Li Y
Hum Pathol; 2018 Nov; 81():192-200. PubMed ID: 30420046
[TBL] [Abstract][Full Text] [Related]
16. When Should Lymphadenectomy Be Performed in Non-Metastatic Pancreatic Neuroendocrine Tumors? A Population-Based Analysis of the German Clinical Cancer Registry Group.
Abdalla TSA; Bolm L; Klinkhammer-Schalke M; Zeissig SR; Kleihues van Tol K; Bronsert P; Litkevych S; Honselmann KC; Braun R; Gebauer J; Hummel R; Keck T; Wellner UF; Deichmann S
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275882
[TBL] [Abstract][Full Text] [Related]
17. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.
Reinert CP; Baumgartner K; Hepp T; Bitzer M; Horger M
Abdom Radiol (NY); 2020 Mar; 45(3):750-758. PubMed ID: 31953587
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry.
Begum N; Maasberg S; Pascher A; Plöckinger U; Gress TM; Wurst C; Weber F; Raffel A; Krausch M; Holzer K; Bartsch DK; Musholt TJ; Keck T; Anlauf M; Rinke A; Pape UF; Goretzki PE;
Langenbecks Arch Surg; 2020 Mar; 405(2):145-154. PubMed ID: 32372309
[TBL] [Abstract][Full Text] [Related]
20. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
Kasai Y; Masui T; Nakakura EK; Nakano K; Sato A; Uchida Y; Yogo A; Nagai K; Anazawa T; Hope TA; Kim GE; Whitman J; Le BK; Takaori K; Bergsland EK; Hatano E; Uemoto S
Pancreatology; 2022 Jan; 22(1):123-129. PubMed ID: 34736838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
